<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013792</url>
  </required_header>
  <id_info>
    <org_study_id>05-011091</org_study_id>
    <nct_id>NCT01013792</nct_id>
  </id_info>
  <brief_title>A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers</brief_title>
  <official_title>A Multi-centered, Prospective, Randomized, Double-blinded, Comparison of an Investigational Non-adherent Dressing to 3M Tegaderm Matrix Dressing With PHI Technology in the Management of Non-healing Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to:

        -  Assess the effect of the Non-adherent study dressing to 3M Tegaderm Matrix Dressing with
           PHI technology on wound healing in patients with a diabetic foot ulcer.

      Secondary objectives are to:

        -  Assess the adverse events that occur in subjects randomized to the investigational
           dressing in comparison to subjects randomized to the Tegaderm Matrix Dressing with PHI
           technology.

        -  Assess the costs of using the investigational dressing compared to the Tegaderm Matrix
           Dressing with PHI technology.

        -  Assess and compare the impact that these dressings have on patients' quality of life.

        -  Assess the wound's biological response and pH to the study dressings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare the effect of an investigational,
      non-adherent dressing to a commercial wound dressing, 3M™ Tegaderm™ Matrix Dressing with PHI™
      technology (Matrix dressing), in the management of diabetic foot ulcers. Subjects' wounds
      will be observed for a four week, pre-treatment period with wound assessments being made and
      samples of wound fluid and tissue collected and analyzed to characterize the wound. Following
      this pre-treatment observational stage, subjects continuing to meet inclusion/exclusion
      criteria will be randomly assigned, with stratification by center, wound size and wound
      duration, in either of two groups in the eight week treatment stage of the study. Subjects in
      one group will have their wound managed with an investigational non-adherent dressing, and
      subjects in the other group will have their wound managed with a Matrix dressing. At Visit 4
      (start of the treatment stage of the study), subjects with a study wound that is less than 1
      cm2 at this point will be dropped from the study. A second investigational device will be
      used to measure the pH of the wound, which will be compared to wound healing data.

      Pre-treatment Stage Secondary Objectives

        1. To measure and compare changes in wound size and wound assessments with changes in wound
           biomarker levels, wound pH, microbial load, and changes in systemic levels of C-reactive
           protein and homocysteine.

        2. To measure and compare changes in wound biomarker levels, pH, and microbial load, and
           changes in systemic (blood) levels of C-reactive protein and homocysteine, looking for
           relationships.

      Treatment Stage Secondary Objectives

        1. To measure and compare the incidence of adverse events experienced by subjects in each
           of the 2 treatment groups.

        2. To measure and compare the wound characteristics of each treatment group.

        3. To measure and compare the subjects' quality of life of each treatment group.

        4. To measure and compare the cost effectiveness of each treatment group.

        5. To measure and compare changes in wound size with changes in wound biomarker levels, pH,
           and microbial load; and changes in systemic (blood) levels of C-reactive protein and
           homocysteine.

        6. To measure and compare changes in wound biomarker levels, pH, microbial load, and
           changes in systemic levels of C-reactive protein and homocysteine, looking for
           relationships within treatment groups and overall.

        7. To assess the ease of using these dressing

      Post-treatment Stage Secondary Objectives

      Subjects whose wounds heal prior to Visit 12 are expected to have a follow-up appointment
      12-14 weeks after their wound has healed. Subjects whose wounds do not heal by Visit 12 are
      expected to complete a follow-up appointment 12-14 weeks after their last appointment. The
      objectives of this are to determine the frequency of complete healing between the two
      treatment groups and to determine the number of wounds that had healed by the end of the
      treatment phase and remained healed for each group at the follow-up appointment.

      The objective is to measure and compare the percentage of wounds healed by Visit 12 (or
      before) that remained healed at the follow-up appointment by treatment group.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Expired study materials; low subject recruitment
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>A positive value indicates a reduction in area relative to baseline, while a negative value indicates an increase in area relative to baseline (at time of randomization), calculated as [(Baseline - Week 8)/Baseline] x 100%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>Non-adherent Wound Dressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegaderm Matrix Dressing with PHI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A commercial wound dressing to be used per manufacturer's instructions for use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wound Dressing</intervention_name>
    <description>Acetate mesh carrier with ointment (water, PEGs)</description>
    <arm_group_label>Non-adherent Wound Dressing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wound Dressing</intervention_name>
    <description>Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)</description>
    <arm_group_label>Tegaderm Matrix Dressing with PHI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is the subject 18 years of age or older?

          2. Does the subject have a chronic full thickness diabetic foot ulcer (DFU) inferior to
             the malleolus that has been present for a minimum of four (4) weeks?

          3. Does the diabetic foot ulcer measure greater than 1.0 cm2 and less than 25.0 cm2 after
             the wound is debrided?

          4. Does the subject show evidence of neuropathy?

          5. Is the subject's wound free of tunneling and showing no exposed periosteum or bone and
             free of clinical infection defined as the presence of local signs and symptoms
             including purulence, warmth, tenderness, pain, induration, cellulitis, bullae,
             crepitus, abscess, fasciitis and osteomyelitis?

          6. Is the study wound able to be off loaded or achieve pressure relief and permit daily
             dressing changes?

          7. Is the subject willing to have three (3) wound biopsies taken (Visit 0, 4 and 8)?

          8. Is the subject willing to have photos taken of their wound and permit use of the
             photos in publications?

          9. Has the subject or their legally authorized representative signed an Institutional
             Review Board approved informed consent document and authorized the use and disclosure
             of protected health information?

         10. Does the subject have adequate circulation to the foot as evidenced by an Ankle
             Brachial Index (ABI) of 0.8 - 1.2; or if the ABI is greater than 1.2, does the subject
             show toe pressures &gt;40 mmHg, or transcutaneous oximetry (TcPO2) &gt; 40 mm Hg, or does
             the subject show adequate circulation on an arterial Doppler study? (ABI or Doppler
             results must be &lt; 45 days old.)

         11. Is the subject able to comply with the protocol requirements?

         12. If the subject is a woman of child bearing potential is she practicing an acceptable
             form of birth control as determined by the Investigator, and is she willing to have a
             pregnancy test?

        Exclusion Criteria:

          1. Is the subject pregnant or breast feeding or have they given birth within the 3 weeks
             preceding the screening visit?

          2. Has the subject been diagnosed with a malignant disease and received chemotherapy or
             treatment for a malignancy within the past 1 year?

          3. Does the subject have an infection requiring systemic antibiotic treatment?

          4. Has the subject ever received radiation therapy or other local therapy for malignancy
             at the extremity where the wound is located (from patient history)?

          5. Is the subject currently using systemic steroids, or have they used systemic steroids
             within the previous 2 weeks, or are they projected to require systemic steroid use
             during the study as evidenced by a history of chronic systemic steroid use? (Topical
             steroids (except on the study extremity) and steroid inhalants will be allowed in the
             study.)

          6. Does the subject have Lupus or Crohn's disease?

          7. Does the subject have an oxygen dependency?

          8. Has the subject received hyperbaric oxygen therapy within the previous 90 days?

          9. Has the subject had vascular surgery relating to the wound within 30 days prior to the
             Screening Visit?

         10. Does the subject have an active Charcot foot deformity of the foot presenting the
             ulcer?

         11. Has the subject received Dermagraft®, Apligraf, or any other biologically active wound
             care product, or used Regranex Gel®, KGF, TGFβ or another topical growth factor to the
             study ulcer within the 30 days prior to the Screening visit?

         12. Does the subject's wound require the use of topical silver, topical antibiotics,
             enzymatic debridement agents or other topical agents?

         13. Has the subject been enrolled in any investigational study within 30 days of the
             Screening Visit?

         14. Does the subject have any medical condition that in the opinion of the investigator
             should exclude him/her from participating in the study?

         15. Has the subject received ultrasonic debridement or electrical stimulation within 7
             days of the Screening Visit?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph V Boykin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCA Retreat Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Terry Treadwell, MD</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alex Reyzelman, DPM</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wyatt Payne, MD</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vickie Driver, DPM</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Marston, MD</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joseph Boykin, MD</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schultz G, Mozingo D, Romanelli M, Claxton K. Wound healing and TIME; new concepts and scientific applications. Wound Repair Regen. 2005 Jul-Aug;13(4 Suppl):S1-11. Review.</citation>
    <PMID>16008735</PMID>
  </reference>
  <reference>
    <citation>Keast DH, Bowering CK, Evans AW, Mackean GL, Burrows C, D'Souza L. MEASURE: A proposed assessment framework for developing best practice recommendations for wound assessment. Wound Repair Regen. 2004 May-Jun;12(3 Suppl):S1-17. Review.</citation>
    <PMID>15230830</PMID>
  </reference>
  <reference>
    <citation>Mustoe T. Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg. 2004 May;187(5A):65S-70S. Review.</citation>
    <PMID>15147994</PMID>
  </reference>
  <reference>
    <citation>Falanga V. The chronic wound: impaired healing and solutions in the context of wound bed preparation. Blood Cells Mol Dis. 2004 Jan-Feb;32(1):88-94. Review.</citation>
    <PMID>14757419</PMID>
  </reference>
  <reference>
    <citation>Xu L, McLennan SV, Lo L, Natfaji A, Bolton T, Liu Y, Twigg SM, Yue DK. Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. Diabetes Care. 2007 Feb;30(2):378-80.</citation>
    <PMID>17259515</PMID>
  </reference>
  <reference>
    <citation>Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med. 2006 Jun;23(6):594-608. Review.</citation>
    <PMID>16759300</PMID>
  </reference>
  <reference>
    <citation>Steed DL. Wound-healing trajectories. Surg Clin North Am. 2003 Jun;83(3):547-55, vi-vii. Review.</citation>
    <PMID>12822725</PMID>
  </reference>
  <reference>
    <citation>Robson MC, Hill DP, Woodske ME, Steed DL. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg. 2000 Jul;135(7):773-7.</citation>
    <PMID>10896369</PMID>
  </reference>
  <reference>
    <citation>Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2003 Jun;26(6):1696-700.</citation>
    <PMID>12766096</PMID>
  </reference>
  <reference>
    <citation>Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol. 2002 Dec;119(6):1420-5.</citation>
    <PMID>12485449</PMID>
  </reference>
  <reference>
    <citation>Sheehan P, Jones P, Giurini JM, Caselli A, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plast Reconstr Surg. 2006 Jun;117(7 Suppl):239S-244S.</citation>
    <PMID>16799391</PMID>
  </reference>
  <reference>
    <citation>Steed DL, Hill DP, Woodske ME, Payne WG, Robson MC. Wound-healing trajectories as outcome measures of venous stasis ulcer treatment. Int Wound J. 2006 Mar;3(1):40-7.</citation>
    <PMID>16650209</PMID>
  </reference>
  <reference>
    <citation>Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol. 2000 May;142(5):960-4.</citation>
    <PMID>10809855</PMID>
  </reference>
  <reference>
    <citation>Greener B, Hughes AA, Bannister NP, Douglass J. Proteases and pH in chronic wounds. J Wound Care. 2005 Feb;14(2):59-61. Review.</citation>
    <PMID>15739652</PMID>
  </reference>
  <reference>
    <citation>Karim RB, Brito BL, Dutrieux RP, Lassance FP, Hage JJ. MMP-2 assessment as an indicator of wound healing: A feasibility study. Adv Skin Wound Care. 2006 Jul-Aug;19(6):324-7.</citation>
    <PMID>16885646</PMID>
  </reference>
  <reference>
    <citation>Pirayesh A, Dessy LA, Rogge FJ, Hoeksema HJ, Sinove YM, Dall' Antonia A, Jawad MA, Gilbert PM, Rubino C, Scuderi N, Blondeel R, Monstrey S. The efficacy of a polyhydrated ionogen impregnated dressing in the treatment of recalcitrant diabetic foot ulcers: a multi-centre pilot study. Acta Chir Belg. 2007 Nov-Dec;107(6):675-81.</citation>
    <PMID>18274183</PMID>
  </reference>
  <reference>
    <citation>van Rossum M, Vooijs DP, Walboomers XF, Hoekstra MJ, Spauwen PH, Jansen JA. The influence of a PHI-5-loaded silicone membrane, on cutaneous wound healing in vivo. J Mater Sci Mater Med. 2007 Jul;18(7):1449-56. Epub 2007 Mar 27.</citation>
    <PMID>17387598</PMID>
  </reference>
  <reference>
    <citation>Schmidtchen A, Wolff H, Hansson C. Differential proteinase expression by Pseudomonas aeruginosa derived from chronic leg ulcers. Acta Derm Venereol. 2001 Nov-Dec;81(6):406-9.</citation>
    <PMID>11859942</PMID>
  </reference>
  <reference>
    <citation>Edwards JV, Howley PS. Human neutrophil elastase and collagenase sequestration with phosphorylated cotton wound dressings. J Biomed Mater Res A. 2007 Nov;83(2):446-54.</citation>
    <PMID>17477392</PMID>
  </reference>
  <reference>
    <citation>Rushton I. Understanding the role of proteases and pH in wound healing. Nurs Stand. 2007 Apr 18-24;21(32):68, 70, 72 passim. Review.</citation>
    <PMID>17479791</PMID>
  </reference>
  <reference>
    <citation>Gethin GT, Cowman S, Conroy RM. The impact of Manuka honey dressings on the surface pH of chronic wounds. Int Wound J. 2008 Jun;5(2):185-94. doi: 10.1111/j.1742-481X.2007.00424.x. Retraction in: Int Wound J. 2014 Jun;11(3):342.</citation>
    <PMID>18494624</PMID>
  </reference>
  <reference>
    <citation>Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993 Jul;101(1):64-8.</citation>
    <PMID>8392530</PMID>
  </reference>
  <reference>
    <citation>Ravanti L, Kähäri VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med. 2000 Oct;6(4):391-407. Review.</citation>
    <PMID>10998429</PMID>
  </reference>
  <reference>
    <citation>Muller M, Trocme C, Lardy B, Morel F, Halimi S, Benhamou PY. Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing. Diabet Med. 2008 Apr;25(4):419-26. doi: 10.1111/j.1464-5491.2008.02414.x.</citation>
    <PMID>18387077</PMID>
  </reference>
  <reference>
    <citation>Schönfelder U, Abel M, Wiegand C, Klemm D, Elsner P, Hipler UC. Influence of selected wound dressings on PMN elastase in chronic wound fluid and their antioxidative potential in vitro. Biomaterials. 2005 Nov;26(33):6664-73.</citation>
    <PMID>15978664</PMID>
  </reference>
  <reference>
    <citation>Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002 Jul;137(7):822-7.</citation>
    <PMID>12093340</PMID>
  </reference>
  <reference>
    <citation>Smeets R, Ulrich D, Unglaub F, Wöltje M, Pallua N. Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. Int Wound J. 2008 Jun;5(2):195-203. doi: 10.1111/j.1742-481X.2007.00367.x.</citation>
    <PMID>18494625</PMID>
  </reference>
  <reference>
    <citation>Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications. 2006 Sep-Oct;20(5):329-35.</citation>
    <PMID>16949521</PMID>
  </reference>
  <reference>
    <citation>Fasciglione GF, Marini S, D'Alessio S, Politi V, Coletta M. pH- and temperature-dependence of functional modulation in metalloproteinases. A comparison between neutrophil collagenase and gelatinases A and B. Biophys J. 2000 Oct;79(4):2138-49.</citation>
    <PMID>11023917</PMID>
  </reference>
  <reference>
    <citation>Nwomeh BC, Liang HX, Cohen IK, Yager DR. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res. 1999 Feb;81(2):189-95.</citation>
    <PMID>9927539</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <results_first_submitted>March 2, 2015</results_first_submitted>
  <results_first_submitted_qc>March 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2015</results_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>Foot</keyword>
  <keyword>Ulcer</keyword>
  <keyword>Neuropathic</keyword>
  <keyword>Tegaderm Matrix Dressing</keyword>
  <keyword>DFU</keyword>
  <keyword>Wound Care</keyword>
  <keyword>PHI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-adherent Wound Dressing</title>
          <description>Wound Dressing: Acetate mesh carrier with ointment (water, PEGs)</description>
        </group>
        <group group_id="P2">
          <title>Tegaderm Matrix Dressing With PHI Technology</title>
          <description>Wound Dressing: Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study suspended</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects had diabetic foot ulcers between 1.0cm2 and 25.0cm2 at randomization</population>
      <group_list>
        <group group_id="B1">
          <title>Non-adherent Wound Dressing</title>
          <description>Wound Dressing: Acetate mesh carrier with ointment (water, PEGs)</description>
        </group>
        <group group_id="B2">
          <title>Tegaderm Matrix Dressing With PHI Technology</title>
          <description>Wound Dressing: Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="7.06"/>
                    <measurement group_id="B2" value="54.1" spread="11.01"/>
                    <measurement group_id="B3" value="56.9" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic foot ulcer area</title>
          <units>cm2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" lower_limit="1.3" upper_limit="11.3"/>
                    <measurement group_id="B2" value="2.8" lower_limit="1.1" upper_limit="14.6"/>
                    <measurement group_id="B3" value="2.8" lower_limit="1.1" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic foot ulcer age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>4-12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27-52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1-5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit</title>
        <description>A positive value indicates a reduction in area relative to baseline, while a negative value indicates an increase in area relative to baseline (at time of randomization), calculated as [(Baseline - Week 8)/Baseline] x 100%.</description>
        <time_frame>up to 8 weeks</time_frame>
        <population>All participants that are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Non-adherent Wound Dressing</title>
            <description>Wound Dressing: Acetate mesh carrier with ointment (water, PEGs)</description>
          </group>
          <group group_id="O2">
            <title>Tegaderm Matrix Dressing With PHI Technology</title>
            <description>Wound Dressing: Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit</title>
          <description>A positive value indicates a reduction in area relative to baseline, while a negative value indicates an increase in area relative to baseline (at time of randomization), calculated as [(Baseline - Week 8)/Baseline] x 100%.</description>
          <population>All participants that are randomized</population>
          <units>percent change of baseline area</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="-70" upper_limit="100"/>
                    <measurement group_id="O2" value="34.2" lower_limit="-43.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>25 Weeks</time_frame>
      <desc>Start at patient consent/screening, through 4-week run-in, through 8 weeks treatment, through 12 weeks post-treatment follow-up</desc>
      <group_list>
        <group group_id="E1">
          <title>Non-adherent Wound Dressing</title>
          <description>Wound Dressing: Acetate mesh carrier with ointment (water, PEGs)</description>
        </group>
        <group group_id="E2">
          <title>Tegaderm Matrix Dressing With PHI Technology</title>
          <description>Wound Dressing: Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Subendocardial myocardial infarction</sub_title>
                <description>Renal failure, resulting in hemodialysis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unexpected death in his sleep</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ulcer/foot infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic event with associate foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Dizzy spells</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound/Skin Infection</sub_title>
                <description>Infection/Cellulitis in wound or periwound skin</description>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sprained ankle</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Disorder</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Upper respiratory infection</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Trauma, Blister</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical resection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis, Edema, Swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph V. Boykin, Jr., MD</name_or_title>
      <organization>HCA Retreat Hospital, Institute of Plastic and Reconstructive Surgery</organization>
      <phone>804-353-8100</phone>
      <email>joseph.boykin@HCAhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

